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Akt/PKB, protein kinase B 
AMPK, AMP-activated protein kinase 
Bcl-2, B-cell lymphoma 2 
CS, chondroitin sulfate 
CSCD, congenital stromal corneal dystrophy 
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EC, endothelial cell 
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mTOR, mammalian target of rapamycin 
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Peg3, paternally expressed gene 3 
PGC1, peroxisome proliferator-activated receptor gamma coactivator 1-
PI3K, phosphoinositide 3-kinase 
PINK1, PTEN induced kinase 1 
RTK, receptor tyrosine kinase 
SHP-1, src homology region 2 domain-containing phosphatase-1 
SLRP, small leucine-rich proteoglycan 
Su9, subunit 9 of mitochondrial ATPase 
TCHP, trichoplein keratin filament binding 
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TFEB, transcription factor EB 
TGF-β, transforming growth factor β 
Thr, threonine 
TIMP3, tissue inhibitor of metalloproteinase 3 
Tyr, tyrosine 
VEGFA, vascular endothelial growth factor A 
VEGFR2, vascular endothelial growth factor receptor 2 
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Decorin is a ubiquitous secreted small-leucine rich proteoglycan associated with 
all major collagen-rich matrices. Initially described for its roles in maintaining the 
structural integrity of various organs and in collagen fibrillogenesis, decorin has 
gained notoriety for its involvement in regulating physiological and pathological 
processes such as wound healing, inflammation, cell adhesion, and 
carcinogenesis.  Decorin exerts these functions through its ability to bind with 
high affinity to multiple receptor tyrosine kinases (RTKs). In cancer, decorin has 
been described as a paracrine tumor repressor and anti-angiogenic molecule. 
However, a detailed description of its mechanism of action in the tumor 
microenvironment was unknown. Understanding the role of the tumor stroma in 
modulating the signaling of cancer cells, tumor angiogenesis, and metastatic 
spreading is critical and of clinical relevance. This thesis unscrambles the 
biology of decorin in the tumor microenvironment and describes a new double 
mechanism of action where decorin alters signaling cascades of both cancer 
cells and surrounding stromal cells via selective binding to different RTKs, 
ultimately elucidating its tumor suppressor activity. The key observations of my 
studies are: [1] the discovery that physical interaction of decorin with the Met 
receptor on cancer cells causes a protracted downregulation of -catenin and 
its downstream effector Myc both at the transcriptional and post-translational 
levels (chapter 3); [2] the discovery that systemic delivery of soluble decorin in-
vivo causes genotypic changes in the stroma of orthotopic breast carcinoma 
xenografts and the identification of Peg3 as a novel decorin-induced tumor 
suppressor in the tumor microenvironment (chapter 5); [3] the observation that 
decorin evokes autophagy in endothelial cells via binding to VEGFR2 and 
induction of Peg3 (chapter 6). Thus, here I define how decorin dually affects the 
tumor proper by suppressing Met activity and the tumor vasculature by inducing 
unrestrained autophagy. Decorin could tie the interplay between extracellular 
signaling and intracellular catabolic pathways that leads to angiostasis and 
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1.1 The extracellular matrix 
The extracellular matrix (ECM) is a complex acellular network of 
macromolecules that function as a scaffold for the growth, biochemical support, 
and homeostatic development of multicellular organisms (1-4). This three-
dimensional meshwork of proteins defines cell polarity and tissue boundaries 
but also serves as a reservoir for growth factors and a versatile substrate for 
cell migration. Two main classes of macromolecules comprise the ECM: 
fibrillary molecules, such as collagen, elastin, fibronectin (FN), and laminin and 
non-fibrillar components such as proteoglycans, and hyaluronan (HA) (4;5). 
Based on structure and composition, two major types of ECMs: pericellular 
matrices and interstitial matrices, can be identified. The basement membrane is 
a specialized type of pericellular matrix found between epithelial cells and 
underlying connective tissue. Most basement membranes are composed by 
sheet-like layers of matrix proteins (mostly collagen IV, laminins, and 
proteoglycans) that anchor and support the epithelium, and is found basolateral 
to all cell monolayers in the body (6;7). In contrast, the interstitial matrix is the 
most abundant reservoir of ECM components in the body and is found in 
interstitial connective tissue. It is characterized by the presence of FN, 
proteoglycans, elastin, and types I, III, V, VI, VII, and XII collagens (4). 
Proteoglycans fill the interstitial space with a hydrated gel-like polysaccharide 
composed by repeated units of disaccharides called glycosaminoglycans 
(GAGs). Proteoglycans exert multiple functions in the matrix, from binding and 
sequestering various growth factors to providing hydration by trapping water 
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molecules for gel formation to confer mechanical support. Proteoglycans also 
interact with fibrous proteins to generate molecular structures that allow the 
forming matrix to withstand compressive forces (8-10). However, the most 
abundant components of the ECM are the fibrous proteins collagen, elastin, FN, 
and laminin. The majority of collagens form a triple-stranded helix that 
aggregates into molecular complexes that function as structural elements of the 
ECM. They regulate cell adhesion, provide tensile strength, and are involved in 
migration and development (5). Several types of collagens have been identified 
in connective tissues that either form fibrils or bind to collagen fibrils to link them 
together. Moreover, collagen associates with elastin fibers, which are abundant 
in those connective tissues undergoing repetitive stretch. Tight associations 
between elastin fibers and collagen fibrils modulate various properties of tissue 
elasticity (4). Another key fibrous protein, FN is a dimeric glycoprotein that 
serves as a primary adhesion molecule of the connective tissue. With binding 
sites for both GAGs and collagens, FN crosslinks these ECM members, as well 
as other growth factors and cell adhesion receptors (11). Lastly, laminin is a key 
structural component of the basal membrane that can interact with collagen, 
proteoglycans, and cell surface receptors (12). Although the ECM is most 
abundant in connective tissues, each tissue has a unique ECM signature and 
ultrastructure characterized by varying ratios of ECM gene expression that 
dictate the structure and function of the tissue. Cartilage, for example, is 
composed of a firm layer of highly concentrated polysaccharides that coneys 
mechanical resistance. Tendons are, instead, characterized by a higher 
expression of fibrous proteins (13). In healthy tissue, non-activated fibroblasts 
secrete and organize collagen fibrils, various proteoglycans like decorin, HA, 
FN and elastin, all of which accumulate in the forming matrix and provide ECM 
functionality and impart tissues with structural integrity. Importantly, in most 
tissues, the ECM undergoes constant enzymatic or non-enzymatic remodeling 
through finely balanced cycles of degradation, synthesis, and deposition. This 
“dynamic reciprocity” (14) characterizes the mechanical proprieties of each 
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tissue, such as elasticity or stiffness, and confer protection by maintaining 
extracellular homeostasis and water retention (15-17).  
A large majority of ECM proteins actively communicate with the 
surrounding cells through binding to various cell surface receptors such as 
integrins, discoidin domain receptors, and receptor tyrosine kinases (RTKs) to 
initiate signaling cascades that control gene transcription, cell growth, 
differentiation, and survival in healthy and diseased tissues (4). In this context, 
the ECM is the primary provider of external stimuli that control cellular behavior 
and function. The bidirectional dialogue between the ECM network and 
embedded cells is essential during tissue development to maintain organ 
function and homeostasis. Dysregulation of this interplay can lead to 
maladaptive changes in ECM composition and architecture (5). As the ECM 
signature dynamically changes in response to stress or injury, the ratio of the 
expression of different ECM components is actively modulated. In cancer, ECM 
remodeling, and aberrant deposition by cancer-associated fibroblasts increase 
the stiffness of the tumor compared to the surrounding tissue and induce 
inflammation (18). The release of various growth factors such as vascular 
endothelial growth factor (VEGFA) promotes neovascularization, fostering a 
malignant phenotype (19). Recently, advances in high-throughput genomic and 
proteomic techniques allowed molecular characterization of the global ECM in 
healthy and diseased tissues. The so-called matrisome, is the collection of ECM 
glycoproteins (FN, laminins, tenascins, etc.), collagens, proteoglycans, and 
ECM-affiliated proteins (secreted factors, enzymes, etc.) whose differential 
expression can be analyzed in various tissues (3). With this method, the 
elucidation of the total composition of different ECMs in healthy and disease 







1.2 Small leucine-rich proteoglycans 
The small leucine-rich proteoglycans (SLRPs) represent the largest and most 
diverse family of proteoglycans, which is composed of 18 distinct 
macromolecules abundantly found in the ECM (10). Each member is 
characterized by a relatively small protein core of 36-42 kDa formed by a central 
region of 10-12 leucine-rich repeats (LRR). SLRPs are ubiquitously expressed 
and are synthesized and secreted into the pericellular space, which then gets 
incorporated into the tissue extracellular matrix. During development, SLRPs 
are widely expressed in all key membranes such as the meninges, pericardium, 
and pleura that surrounds all major organs. The 18 SLRPs known today are 
divided into five classes based on protein homology, intron-exon organization 
of their genes, chromosomal organization, evolutionary conservation, and the 
presence of N-terminal cysteine-rich clusters of four characteristic cysteine 
residues with defined spacing (10;20). The heterogeneous nature of the GAG 
chains, which are post-translationally and covalently attached to the N-terminus 
of the core protein of some SLRPs, also differentiates the five classes. The first 
distinction comes from the presence or absence of the GAG chain. Only 
members belonging to class I-III possess a GAG chain and are therefore 
considered canonical SLRPs. Almost all class I SLRPs have chondroitin sulfate 
(CS) or dermatan sulfate (DS) chains flanking their LRRs at the N-termini. Class 
II members are, instead, composed of poly-lactosamine or keratin sulfate (KS) 
chains. Class III members are more heterogeneous and contain a mixture of 
either CS/DS, KS, or no GAG chains may be present at all. Finally, classes IV 
and V are considered non-canonical as members of these classes do not 
undergo post-translational modification in the form of GAG chain addition. Still, 
they share structural homology with other SLRPs. At the genomic level, 
chromosomal clustering of the 18 SLRP genes on seven different chromosomes 
suggests they developed by chromosomal duplication. Although the 
significance of SLRP gene clusters is currently unknown, it indicates a degree 
of genetic redundancy and potential functional compensation (20;21).  
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The key distinguishing structural feature and reason for this eponymously 
named class of ECM molecules is the variable numbers of LRRs present in the 
central region of the protein. Each LRR is composed of a conserved 
hydrophobic motif where multiple leucines can be substituted by isoleucine, 
valine, or other hydrophobic amino acids. These LRRs form characteristically 
curved solenoidal structures, where each repeat functions as a single turn of 
the solenoid. Whether each individual LRR constitutes a functional unit of the 
SLRP or clusters of them confer function, akin to zinc fingers in a transcription 
factor, remains to be elucidated. Regardless of their classification, all SLRPs 
share similar biological functions, including the ability to bind to different 
collagens and cell surface receptors to modulate various intracellular signaling 
pathways (9;21;22). Class I SLRPs include decorin, biglycan, asporin, and 
ECM2. A distinctive feature of this class is the unique N-terminal Cys-rich 
consensus sequence that form two disulfide bonds and differs from any other 
class of SLRPs (23). Decorin and its closest relative, biglycan, share ~65% 
overall homology at the amino acid level and both are encoded by similar genes 
of eight exons with highly conserved intron/exon junctions (23). Biglycan 
contains two Ser-Gly attachment sites at the N-terminus for two CS/DS chains, 
hence its name. Conversely, asporin, lacks the typical Ser-Gly sequence 
required for glycanation and, therefore, does not contain a covalently attached 
GAG chain. However, asporin is still considered a Class I SLRP as it has a 
similar exonic organization with highly conserved intron/exon junctions similar 
to decorin and biglycan. ECM2 is the latest addition to the Class I SLRPs. The 
protein core of ECM2 is 35% identical to that of decorin. Moreover, both asporin 
and ECM2 are linked on chromosome 9 (20). 
 
1.3 Decorin: structure and function 
An extensively studied member of the canonical Class I SLRPs is decorin, 
whose gene is located on chromosome 12 (24). Originally investigated in the 
context of collagen fibrillogenesis (25), decorin owes its name to the unique 
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ability to bind and “decorate” collagen fibrils. Synthetized primarily by fibroblasts 
and myofibroblasts, decorin is ubiquitously expressed in most extracellular 
matrices. During development, its primary localization is in the membranes that 
envelop all primary organs, suggesting a role in regulating organ formation 
(1;26). Decorin was the first secreted proteoglycan to be linked to the control of 
cell growth via blockage of transforming growth factor  (TGF), opening new 
and unexplored research avenues in the field of matrix biology, especially as it 
relates to human diseases (27). Since then, decorin has been described not 
only as a structural entity but also as one of the most versatile proteoglycans 
able to regulate a vast range of biological functions (27). Decorin has crucial 
roles in the control of angiogenesis (28), myocardial infarct (29), innate immunity 
(30), inflammation (31), fibrosis (32), wound healing (33), regulation of corneal 
wound healing (34), and autophagy (35). This repertory of functions arises from 
the ability of decorin to interact with numerous ligands in the ECM, mainly 
growth factors, and to evoke intracellular signaling cascades through binding to 
cellular receptors (36). These intricate interactions engage both decorin GAG 
chain as well as specific binding motifs in its LRR rich protein core (Fig. 1). The 
crystal structure of decorin shows the proteoglycan shaped like a horseshoe 
with the inner concave surface structurally defined by 14 curved -sheets and 
the outer convex surface by multiple -helices (37) (Fig. 1). It is the concave 
surface of the arc-shaped decorin protein core, with leucine placed in conserved 
positions as predominant hydrophobic residues that mediates the physiological 
ability of decorin to bind ECM components and receptors, with high affinity (38). 
Each LRR, composed of an average of 24 amino acids, has a unique biological 
function and binding constant. The primary physiological function of decorin in 
normal tissue is the control of collagen fibrillogenesis (36). Site-directed 
mutagenesis studies of decorin LRR IV-VII revealed a direct collagen-binding 
site (39;40). Decorin binds to a region of collagen type I, close to the 
intermolecular cross-linking site at its C-terminus. Stoichiometrically, a singular 
molecule of decorin can bind to four to six collagen molecules at the D period of 
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the collagen type I molecule (41). This non-covalent, and presumably reversible 
binding regulates collagen fibril assembly and cross-linking with delayed 
assembly and constriction of the final diameter of the collagen fibers (42). 
Decorin-deficient mice are characterized by non-uniform, irregularly shaped 
collagen fibrils in the skin (43). This anomalous collagen network assembly 
allows for full-body development but leads to skin fragility and an irregular 
healing process.  Notably, the N-terminal O-linked DS GAG chain of decorin can 
also simultaneously bind to adjacent collagen fibers and participate in collagen 
fibril formation during development (44). Decorin can also bind collagens II-XII 
and XIV (36). Other members of the SLRP family are involved in the regulation 
of collagen fibril assembly in connective tissue, as shown in various SLRP 
knockout animal models. For instance, biglycan null animals show a propensity 
for osteoarthritis and bone mass reduction (45). Osteoarthritis is also found in 
mice lacking fibromodulin, whereas lumican knockout causes corneal opacity 
and a skin fragility phenotype akin to decorin (46).  
A crucial function of decorin and other SLRPs is the binding of growth 
factors and the subsequent regulation of their downstream signaling activities. 
Dysregulation of TGF is the hallmark of fibrotic diseases characterized by 
excessive and aberrant matrix deposition. Decorin binds and neutralizes 
TGFactivity, ultimately preventing rampant fibrosis (16;47). Moreover, through 
LRR IV-VI, decorin binds and antagonizes multiple RTKs, such as the vascular 
endothelial growth factor receptor 2 (VEGFR2) in extravillous trophoblasts 
through LRR V/VI (48;49), and the epidermal growth factor receptor (EGFR) 
(50). A structural feature of decorin, which is shared by different SLRPs, is the 
presence of the so-called ear repeat at the C-terminal LRR XI (Fig. 1). The ear 
repeat extends laterally from the solenoid structure of the main protein and 
consists of a cysteine in LRR XI that forms a disulfide bond with another cysteine 
in the terminal LRR XII (51). This results in LRR XI being longer (30 amino acids) 
than the other LRRs in the decorin protein core. The ear repeat is believed to 
participate in protein folding, as shown in a mouse model of congenital stromal 
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corneal dystrophy (CSCD). This genetic disease is characterized by the 
truncation of the last 33 amino acid residues in the C-terminal domain, which 
includes the ear repeat. The mutation leads to intracellular accumulation of 
misfolded decorin and activation of the ER stress response, ultimately leading 
to visual impairment and corneal opacification in mice (52). Corneal specimens 
of patients affected by CSCD showed abnormal stroma and dysregulated 
fibrillar collagen structures due to the intracellular accumulation of truncated 
decorin (38). Decorin naturally undergoes dimerization, although it is the 
monomeric form that is responsible for most of its interactions, as dimerization 
prevents exposure of the core binding regions found on the concave surface of 
the protein (53). In this aspect, decorin alternates between forming homodimers 
and binding to collagen type I as a monomer (53). Importantly, dimerization of 
the protein core of decorin was found to be not necessary for decorin stability 
(53). Through its interactive network, decorin sequesters growth factors in the 
ECM (54;55), governs receptor-signaling events (56), and modifies the 
processing of other critical components of the matrix (57). The ability of decorin 
to alter intracellular signaling pathways from the matrix has tremendous 
implications in clinical oncology as decorin may function as a valid therapeutic 












1.4  Decorin expression in solid tumors 
To better understand the biological effects of decorin in cancer, it is necessary 
to investigate its expression patterns and localization within the tumor 
compartments. There are several incongruences in the literature when it comes 
to decorin expression levels in different types and grades of tumors. In invasive 
breast carcinoma, loss of decorin in the tumor microenvironment is associated 
with a poor prognosis (58). Moreover, a query of the Human Protein Atlas 
Database demonstrated a marked reduction in the expression levels of decorin 
in the stroma of various tumors, including breast, colon, cervical, and ovary 
carcinomas (59). In the stroma of low- and high-grade bladder cancers, decorin 
is significantly reduced within the tumor stroma (60) as well as in cases of 
esophageal squamous cell carcinoma (61) and colon cancer (62). However, 
other studies reported elevated amounts of decorin in the stromal compartment 
of certain tumors, including colon and breast carcinomas (63). Given the ample 
Figure 1. Graphical representation of the crystal structure of monomeric bovine decorin 
created via Pymol v1.7 (PDB accession number 1XKU) depicting its curved appearance 
and leucine rich repeats. LRR 4–6 are important for binding of decorin to collagen and 
receptor tyrosine kinases, including VEGFR2 and EGFR. The ear repeat at the C-terminal 




range of components of the extracellular matrix that binds to decorin, we can 
argue that its overexpression in the stroma of these tumors may negatively 
regulate growth by sequestering growth factors and downregulating RTKs 
present on the adjacent tumor cells. Pertinent to the tumor parenchyma, 
different studies have shown complete loss of decorin expression by the cancer 
cells of prostate, urothelial, and hepatic malignancies (64). In some neoplasms, 
the decorin promoter results hypermethylated, thus allowing unchecked tumor 
progression through silencing of decorin (64). Further evidence for the 
oncostatic role of decorin comes from genetic models of decorin ablation (43). 
If fed with a high-fat diet, decorin null mice develop spontaneous intestinal 
tumors (65). Moreover, a combined knockout mouse model of decorin and p53 
results in the development of aggressive lymphomas (66), whereas 
reintroduction of decorin via adenoviral delivery or systemic administration of 
exogenous decorin significantly counteracts the tumorigenic and angiogenic 
growth in a variety of solid tumors (67;68). Collectively, these studies provide 
robust support for a general tumor-suppressive role of decorin in multiple solid 
tumors. 
 
1.5  Decorin: a guardian from the matrix 
A significant part of the studies on the molecular mechanisms of decorin in 
tumorigenesis and angiogenesis is based on decorin’s avid binding to RTKs on 
the cell surface of cancer cells. Decorin has been described as a guardian from 
the matrix (64) for its innate ability to oppose cancer growth via the 
sequestration of growth factors in the ECM and via the direct antagonism of 
several RTKs (36;69). This definition is based on multiple key observations 
derived from the plethora of decorin-binding molecules (Fig. 2).  For many years, 
EGFR, the first-ever described RTK to bind decorin, has been believed to be 
the only receptor on cancer cells whose signaling was modulated by decorin 
interaction (70). Decorin antagonizes EGFR activity by triggering dimerization 
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of the receptor and internalization through the caveosomes, ultimately leading 
to degradation in the lysosomes and induction of p21WAF1 coincident with cell 
cycle arrest (71). Decorin competes with EGF, the natural ligand of EGFR, and 
exerts a potent physiological down-regulation of EGFR on cancer cells, affecting 
the growth of several types of solid tumors in which EGFR play a key role (72). 
In 2009, a new study revealed an additional RTK affected by decorin. In an RTK 
phosphotyrosine array, Met, the receptor for the hepatocyte growth factor, was 
found phosphorylated in quiescent cells stimulated with decorin for 15 min (73). 
In HeLa cells, decorin-evoked degradation of Met happens through association 
to caveolin-1 and concomitant lysosomal degradation. This is in contrast with 
the canonical endosomal sorting and recycling to the plasma membrane of Met 
upon binding to the hepatocyte growth factor (HGF), suggesting a selective 
mechanism of action of decorin that dictates a different biological outcome. 
Additional members of the epidermal growth factor receptor family of RTKs 
(ErbBs) have been shown to interact with decorin. Significantly, ErbB4 signaling 
is directly antagonized by the binding of decorin to the receptor (74). Decorin 
prevents ErbB4 to dimerize with ErbB2, ultimately causing growth inhibition of 
breast carcinoma cells (74).  Decorin-binding to various RTKs usually stimulates 
receptor internalization and degradation. However, this is not the case for the 
insulin growth factor receptor type I (IGF-IR). Differently from the other RTKs 
studied, IGF-IR is not internalized and degraded by decorin in urinary bladder 
carcinoma, but the binding of decorin to the receptor and its natural ligand IGF-
I leads to inhibition of migration (60). Lastly, decorin antagonizes VEGFR2 in 
trophoblastic (EVT) cells (48) and in endothelial cells (ECs) (35), resulting in 
downstream attenuation of ERK1/2 pathways and induction of autophagy (35), 
a biological process which will be discussed later. Importantly, Met is the primary 
receptor for decorin’s activity in tumor cells. This conclusion is based primarily 
on the binding constants for decorin on various cell surface RTKs. Empirically, 
the Kd of decorin/Met interactions is tighter than the other known constants, 
such as decorin/EGFR, decorin/VEGFR2, and decorin/IGF-IR (36). Indeed, 
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decorin exhibits a hierarchical affinity for its various RTK targets. Functionally, 
pharmacological blockage of Met kinase activity, but not of EGFR activity, 
abolishes decorin-evoked downregulation of -catenin in HeLa cells (73). 
Decorin might evoke intracellular cross-talk signaling events via multiple 
receptor binding, which ultimate in tumor growth arrest. This mechanism is in 
perfect accordance with the emerging body of evidence that stresses the action 
of soluble decorin as a paracrine tumor repressor whose absence is permissive 




Figure 2. Decorin interactome, encompassing different cellular and extracellular components to which 
decorin physically binds through high-affinity interactions and negatively or positively regulates. 






In this thesis, I sought to determine the mechanism of action of decorin within 
the tumor microenvironment, a complex biological system that governs cancer 
initiation, recurrence, and metastasis. The tumor microenvironment 
encompasses extracellular matrix proteins, and stromal cells like fibroblasts, 
immune cells, and ECs essential for tumor vascularization. The balance 
between pro- and anti-angiogenic factors is finely regulated by synergy among 
the components of the tumor microenvironment and the proper cancer cells. In 
this context, the lack of an in-depth analysis of the role of decorin in regulating 
tumor-stroma interactions, as well as the composition of the tumor 
microenvironment, represented a significant gap in the study of decorin anti-
angiogenic and anti-tumorigenic activity. Moreover, until recently, most of the 
emphasis on cancer research has focused on the biology of primary tumors 
rather than on the tumor microenvironment. Although most cancer-related 
deaths are the result of metastatic disease, some deaths are due to other 
factors, such as an overwhelming tumor stroma response. The factors 
contributing to cancer-related mortality require further exploration to facilitate 
the development of novel targeted treatments. Thus, studies to determine how 
the microenvironment can be targeted to prevent tumor initiation, progression, 
and metastasis are warranted. Decorin, a secreted proteoglycan physiologically 
bound to collagen, serves as a primary therapeutic candidate given that its 
absence in the tumor microenvironment favors cancer growth. With my studies, 
I dissected the mechanism of action of decorin on both the tumor stroma and 
cancer cells, further elucidating its biology. By hitting both compartments, 
decorin commences an anti-angiogenic and pro-autophagic program that 






Decorin antagonizes Met receptor activity 
My initial studies explored the discovery that decorin binds to Met receptor with 
higher affinity than EGFR (KD circa 2 nM) (73). I became interested in this 
subject as this observation opened new research possibilities for the 
interpretation of the role of decorin in tumorigenesis and angiogenesis (75). 
Indeed, Met and its natural ligand, the hepatocyte growth factor (HGF), are 
essential to embryonic development. Deregulation of their signaling is often 
associated with tumorigenesis and metastasis, usually through overexpression 
of the receptor. Met interaction with decorin causes receptor degradation 
through translocation into caveolin-1 positive endosome post-recruitment of c-
Cbl to Met at Tyr1003 phosphorylation site (73). This mechanism ensures a 
protracted cessation of Met oncogenic signaling similar to the effects exerted by 
decorin on EGFR signaling and in net contrast with HGF/Met canonical 
signaling. My contribution to this line of research lies in the discovery that 
decorin’s antagonistic activity on Met causes downregulation of two key 
oncogenes, -catenin and its downstream effector Myc via the 26S proteasome 
(76). Myc, a well-characterized critical oncogene involved in the pathogenesis 
of multiple types of cancers (77), is markedly down-regulated by decorin 
treatment both at the transcriptional and post-translational levels in cancer cells. 
Dissection of this mechanism explained decorin anti-tumorigenic activity and 
generated new insights into the use of decorin as a novel therapeutic modality 









Figure 3. Tumor-suppressive action of decorin on cancer cells upon direct binding to Met. Decorin 
binding to Met causes a rapid phosphorylation of the receptor followed by caveolar endocytosis and 
degradation, and cessation of Met oncogenic signaling. Moreover, decorin triggers proteasomal 
degradation of -catenin under Met control, as this effect can be abolished by blocking the kinase 
activity of the receptor. Decorin also phosphorylates Myc at Thr58 and targets it for degradation by the 
proteasome. This latter effect could be mediated by the antagonism of decorin to different RTKs on 
the surface of cancer cells. 
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3.1  Decorin/-catenin/Myc signaling axis 
Of clinical relevance is the fact that the binding of decorin to Met results in the 
reduction of primary tumor growth and metastatic spreading. Suppression of -
catenin and Myc levels lead to inhibition of multiple pathways under the control 
of Met, such as proliferation, migration, survival, and scattering. In particular, 
downregulation of Myc protein levels occurs via decorin-induced 
phosphorylation of Myc at Thr58 (78), a known phosphorylation site that evokes 
Myc degradation via the proteasome. Interestingly, Myc targets AP4, a 
transcriptional repressor of p21WAF148, a cyclin-dependent kinase inhibitor 
whose expression is induced by decorin in cancer cells (79). Moreover, the 
transcriptional downregulation of Myc, further boosts decorin oncostatic effects. 
Decorin might also be utilizing Met-independent pathways in suppressing Myc 
levels in HeLa cells, as reducing the expression of Met with specific siRNA is 
not sufficient for Myc downregulation, suggesting that Myc regulation is Met 
independent (73). Of note is that decorin silencing of -catenin signaling occurs 
in a non-canonical manner independent of GSK-3. Decorin targets -catenin 
for proteasomal degradation by inducing phosphorylation via Met, causing an 
overall stall in tumor growth (73). To corroborate this, in vivo studies utilizing 
orthotopic squamous cell and mammary carcinoma models showed a significant 
reduction of tumor growth three weeks after systemic administration of 
exogenous decorin (58;67). Importantly, decorin shows a specific tropism in vivo 
for cancer cells. Indeed, infrared-labeled decorin injected in mice bearing 
xenografts targets explicitly the tumor mass for up to 68 hours post-injection. 
Except for the liver and the kidneys where decorin is metabolized and cleared, 
no other organs showed intake of the protein. My studies strengthen the 
potential use of soluble decorin as a therapeutic agent for solid malignancies 
and are a critical contribution to the field as they highlight the direct 
oncosuppressive mechanism of decorin action. Notably, systemic or 
adenovirus-mediated delivery of decorin in animals bearing various types of 
malignant xenografts markedly suppresses tumor growth and metastasis in 
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several independent studies (58;80-84). Collectively, these results describe for 
the first time a link between decorin, a secreted proteoglycan, and key 
oncogenic signaling proteins such as Met, -catenin and the multifunctional Myc 
transcription factor. Furthermore, non-canonical governance of β-catenin by 
decorin may underlie the mechanism of intestinal tumor formation following 
decorin ablation. Intestinal epithelium turnover and maturation are propelled by 
β-catenin (85). Met is constitutively activated in colon carcinoma and directly 
influences β-catenin signaling (86). Given that global loss of decorin 
derepresses multiple RTKs in two distinct chemically induced models of 
hepatocellular carcinoma (87), malignant transformation of the intestinal 
epithelium (or other solid malignancies) is triggered by interfering with the Met/β-
catenin axis. Lefebvre et al., 2012 described how Met degradation is an 
attractive novel strategy for tumor therapy given its overexpression and 
transforming activity in cancer cells. In this contest, by preventing Met/HGF 
binding, and thus activation of the receptor, decorin forestalls Met-induced cell 
transformation (88). Baghy et al., 2016 also noticed that decorin could serve as 
a tumor suppressor in liver cancer given the ability to downregulate -catenin 
and Myc. Notably, lower levels of decorin mRNA are reported in liver cancer, 











Decorin antagonizes the angiogenic network 
The description of the signaling events evoked by decorin through binding to 
Met has advanced the matrix biology research field, as it reinforces the role of 
the ECM in restraining tumor progression (18;89;90). A critical cancer hallmark 
and an important factor contributing to the growth and spreading of cancer cells 
is tumor angiogenesis. In this context, Met targeting by decorin is key for 
suppression of tumor angiogenesis in cervical and breast carcinomas, where it 
blocks HGF-induced vascularization in vivo (91). These initial findings have 
influenced my colleague Dr. Neill to investigate and reveal a more intricate 
signaling cascade upon decorin binding to Met that supports its antiangiogenic 
effects. He found that decorin exerts a robust angiostatic activity to counteract 
neo-vascularization by inducing two anti-angiogenic proteins, Thrombospondin 
1 and TIMP3, and by concurrently inhibiting two influential pro-angiogenic 
factors, the hypoxia-inducible factor 1 (HIF-1) and the vascular endothelial 
growth factor A (VEGFA) (91;92). Mechanistically, decorin transcriptionally 
represses HIF-1 as well as the already mentioned oncogenes -catenin and 
Myc under normoxic conditions, further contributing to angiostasis. Ultimately, 
the suppression of these genes critically impairs Met-evoked VEGFA 
transcription. This is critical as, in a feedback loop, loss of HIF-1 inhibits 
expression of Met (93), compromising the ability of cancer cells to respond to 
the scatter factor HGF. Thus, decorin, by binding to Met, significantly mitigates 
important mechanisms of cancer progression and tumor angiogenesis that 
sustain cellular growth and proliferation. Moreover, decorin induces two key 
angiogenic inhibitors, TIMP3, and thrombospondin-1 in the tumor 
microenvironment, thus decreasing tumor growth by actively inhibiting 
intracellular signaling events and by hindering blood supply to tumor cells 
altering the tumor secretome and microenvironment (Fig. 4).  This study 
functionally links decorin and the Met signaling axis to the regulation of 
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pathological VEGF-mediated angiogenesis and provides a mechanism of action 
for decorin in inhibiting a key cancer hallmark. By acting on the tumor cells, 
decorin suppresses VEGFA expression at both transcriptional and post-
transcriptional levels, thus inhibiting de novo formation of blood vessels in the 
surrounding microenvironment. In particular, the concurrent reduction of matrix 
metalloproteinase 2 (MMP-2) activity coupled with induction of thrombospondin-
1 and TIMP3 induces angiostasis in the matrix, acting to further restrict matrix-
bound VEGFA from engaging cognate receptors (e.g., VEGFR2) on the surface 
of tumor ECs. Importantly, thrombospondin-1 expression is negatively regulated 
by Myc. The accumulated data revealed a mechanism where decorin inhibits 
tumor growth in multiple ways. This study is an important contribution to cancer, 
signal transduction, protease, and proteoglycans fields because it described a 
potent angiostatic effect for decorin in the initial phases of tumor angiogenesis. 
At this stage of tumor progression, before the activation of the angiogenic 
switch, tumor hypoxia is incapable of inducing tumor vascularization. The action 
of soluble decorin in this context delineates a compelling mechanism for this 
secreted proteoglycan as a modulator of early angiogenic events. The relevant 
role of the ECM in regulating tumor angiogenesis is well documented. Specific 
proteoglycans tightly interact with vascular cells in the ECM and can alter their 
phenotype, control vascular disease, and act as a molecular rheostat to inhibit 
or promote angiogenesis (19;94;95). The sprouting of novel blood vessels to 
supply oxygen to malignant tumors is orchestrated by crosstalk between 
migrating ECs and cancer cells. In this context, the vascular basement 
membrane, a type of ECM enriched in collagen type IV, laminin, perlecan, and 
other molecules, guides both physiological and malignant angiogenesis (27). 
Under normal conditions, angiogenesis, the process of new blood vessel 
formation from pre-existing ones, is strictly managed by a balance of activators 
and inhibitors. It is essential for embryonic development, and physiologically 
occurs during wound healing and the menstruation cycle. The initial step 
involves the release of pro-angiogenic triggers such as VEGFA, fibroblast 
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growth factor (FGF), platelet-derived growth factor (PDGF), etc. following tissue 
hypoxia or inflammation (96). ECs respond to this stimulus by enzymatically 
degrading the basement membrane through the activation of MMPs and other 
proteinases to clear the path for EC migration and proliferation (97). Once ECs 
have assembled in new vessels, they become metabolically quiescent phalanx-
like cells that form stable interactions with the surrounding pericytes through a 
matured vascular basement membrane. In stark contrast, in cancer the balance 
between anti- and pro-angiogenic factors is compromised and is highly skewed 
to favor the latter. Hypoxic tumor cells excessively secrete pro-angiogenic 
factors (VEGFA, FGF, etc.), and cytokines which activate ECs, and remodel the 
ECM to favor growth (7). In this environment, tumor ECs lose their phalanx-like 
properties, coverage by pericytes, and become excessively and aberrantly 
Figure 4. Schematic representation of decorin angiostatic activity in cancer cells mediated by direct 
binding to the Met receptor. 
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fenestrated. Proteases break down the basement membrane allowing exposure 
of soluble factors that can further stimulate malignant proliferation of tumor ECs 
towards the cancer mass (98). Compared to healthy ECs, tumor ECs present 
increased tube-formation abilities, chromosomal anomalies, and are resistant to 
senescence due to VEGFR2 overexpression and various other cytokine 
receptors (99). Moreover, the vascular basement membrane becomes loosely 
attached to tumor ECs and pericytes, allowing for vascular permeability and 
tumor intravasation (99). The anti-oncogenic properties of decorin have been 
confirmed in various preclinical (59;80-82;84;100-103) and genetic studies 
utilizing Dcn-/- mice where lack of decorin has been shown to be permissive for 
tumorigenesis (65;66;87;104) strengthening our hypothesis that decorin could 

















Decorin affects the gene expression profile of the tumor 
microenvironment 
Decorin-evoked angiostasis through direct binding to RTKs on the tumor cell 
membrane and consequent inhibition of endogenous VEGFA expression 
presented decorin as a stromal-derived tumor repressor. My work showed the 
mechanism that allows decorin to target for degradation essential oncoproteins, 
such as -catenin and Myc, thereby counteracting changes in the gene 
expression signature that would otherwise foster cancer growth. Since decorin 
is a secreted proteoglycan and acts as a soluble paracrine factor on the tumor 
proper, my next research question was to identify potential alterations evoked 
by decorin in the gene expression profile of the tumor microenvironment. This 
intricate compartment constantly evolves and interacts with the cancer cells to 
permit growth and neovascularization. To dissect the relationship between 
tumor stroma and parenchyma, I utilized a well-known human triple-negative 
breast carcinoma model and investigated gene expression changes, not only in 
the cancer cells but specific to the tumor microenvironment as well, following 
systemic administration of decorin. My experiments demonstrated that soluble 
decorin, acting in a paracrine fashion, altered the gene signature of the tumor-
stromal compartment, as evidenced by the differential modulation of 374 
stromal genes (68). My work further elucidates the relevance of the stromal 
matrix in cancer progression and how alteration to the stromal compartment can 
interfere with cancer growth. The initial observation was that mice bearing MDA-
MB-231 xenografts and treated with decorin every other day for a total of 23 
days showed a decreased growth rate compared to the untreated control group 
of mice and a smaller tumor volume at the end of the experiment (Fig. 5).  
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I decided to analyze the tumor tissues with the NimbleGen microarray to 
measure simultaneously the expression of transcripts derived from both the 
mouse (i.e., the stroma) and the human (i.e., the tumor cell line, MDA-MB-231). 
At that time, this innovative technology, in contrast with conventional 
microarrays, allowed to differentiate and profile 720,000 transcripts from both 
Homo sapiens and Mus musculus origin in the same sample and on the same 
array. The advancement of this investigation lies in the prevailing view of the 
tumor stroma as a central compartment heavily activated by cancer cells to 
promote growth and neovascularization. Thus, exploring genes that modulate 
the tumor stroma itself could provide novel targets for therapeutic intervention. 
With this technology, I identified stromal gene expression signatures altered by 
systemic delivery of decorin and, therefore, explored the activity of soluble 
decorin as a paracrine factor in the microenvironment of a growing human 
tumor. My analysis revealed that most of the stromal genes suppressed by 
decorin belonged to the immune response, whereas in the upregulated group 
of genes, I found many cell adhesion and tumor suppressor genes. Independent 
validation of the top 12 genes demonstrating >2-fold up- or down-regulatory 
changes identified Mrgpra2, Siglech, Irg1, and Il1b to be suppressed concurrent 
with induction of  Zc3hav1, Peg3, and Bmp2k (68) (Fig. 6). These data propose 
Figure 5.  Representative macroscopic photographs of control and decorin-treated animals bearing 




decorin as a tumor repressor able to alter the tumor secretome overall, 
attenuating inflammation and metastatic spreading. My followed up studies 
focused on Peg3 as it possesses unique and distinctive characteristics: the 
paternally expressed gene 3 is an imprinted gene whose paternal allele is 
exclusively responsible for expressing a molecule which contains 12 Krüppel-
type zinc finger domains with two proline-rich periodic repeat domains and is 
often inactivated in several malignancies (105). Multiple studies of this gene 
described a role for Peg3 as a tumor suppressor. Moreover, the N-terminal 
SCAN domain of Peg3 mediates direct binding to β-catenin and promotes 26S 
proteasomal degradation that is independent of GSK3β (106). These studies 
are highly interesting because they recapitulate the pathway utilized by decorin, 
in cancer cells, for the non-canonical, GSK3β-independent antagonism and 
inhibition of β-catenin signaling (76) and could provide a vital link between 
decorin-evoked attenuation of RTK signaling, via Met, and non-canonical β-
catenin antagonism. Moreover, an analysis of PEG3 expression in publicly 
available databases of published microarrays, revealed a statistically significant 
decrease of PEG3 mRNA in invasive ductal breast carcinoma, confirming its 
role as a tumor suppressor and providing further clinical validation of the critical 
role of PEG3 in, at least, human ductal breast carcinomas. Most importantly, for 
my research area, these studies provide significant relevance for the newly 
discovered decorin-evoked induction of Peg3 in the microenvironment of breast 
carcinoma and provide a new mechanism for decorin in inhibiting 
tumorigenesis. Validation of the mixed microarray data, as it pertains to stromal 
gene changes, via several experimental methodologies performed in vitro and 
in vivo, confirmed involvement for Peg3 in breast carcinomas. Future studies 
may reveal direct functions for Peg3 in modulating the surrounding tumor 
environment upon decorin stimulation. These findings provide a new model for 
decorin protein core in controlling the tumor microenvironment as a fundamental 
biological mechanism with implications for curbing tumorigenic growth by the 
induction of tumor suppressor genes within the stroma, and for the discovery of 
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novel gene signatures that could eventually help clinical assessment and 
prognosis.  The role of exogenous decorin in altering the gene expression 
signature of the tumor stroma could also be investigated in different types of 
tumors where decorin expression is usually suppressed to find common 
pathways for decorin-evoked oncosuppression. Bozoky et al., 2014 explored 
decorin expression levels in different human tissues compared to the 
corresponding tumors. Decorin was highly expressed in the stroma of the 
Figure 6.  Heat map representing the top 36 genes downregulated (n = 12) or upregulated 
(n = 15) in the mouse tumor stroma in control and decorin-treated mice. Modified from 
Buraschi et al. (39) 
34 
 
healthy tissues examined but was absent or significantly reduced in the tumors. 
Moreover, a parallel comparison of three additional small leucine-rich 
proteoglycans, whose structures are very similar to the one of decorin, revealed 
a different pattern of expression (59). Indeed, asporin and biglycan showed the 
opposite pattern, with negative levels of expression in healthy tissue controls 
and elevated levels in the stroma of the relative tumors. In addition, Yamada et 
al., 2019 found a lack of decorin mRNA in three different lung cancer cell lines 
(107). Therefore, decorin lacks in the tumor microenvironment of different solid 
tumors where its absence allows dysregulated cancer growth. Re-introduction 
of this proteoglycan could be a valid therapeutic strategy as it sequesters 
important growth factors and alters the stromal gene expression signature and 
















Decorin induces autophagy in endothelial cells and causes 
angiostasis 
A highly significant contribution to the matrix biology field and a breakthrough in 
my research efforts is the serendipitous discovery that decorin evokes 
excessive autophagy in ECs, independently of nutrient deprivation, through 
partial agonistic activity on VEGFR2.  In the last few years, the interest in the 
molecular machinery that regulates autophagy has tremendously increased. No 
one has previously shown that a secreted proteoglycan can modulate the 
autophagic program. This initial discovery jump-started an investigation that 
revealed a much more complex interplay between decorin and catabolism. 
Autophagy, an evolutionarily conserved eukaryotic process, promotes 
nonspecific turnover of cytosolic components, proteins, membranes, and 
cellular organelles that are no longer needed to the cell. ECs, a surrogate for 
the tumor microenvironment, are the primary cell type responsible for 
neovascularization (108). These cells are highly sensitive to decorin that, via 
binding to VEGFR2, markedly suppresses VEGFA expression, the main EC 
survival factor (64). The first line of evidence came from the empirical 
observation that stimulation of human umbilical vein endothelial cells (HUVEC) 
or mouse microvascular dermal endothelial cells (MDEC) with decorin caused 
the formation of large vacuoles reminiscent of autophagosomes (Fig. 7). 
Immunofluorescence analysis of these structures showed expression and co-
localization of the autophagic markers microtubule-associated protein 1 light 
chain 3 alpha (LC3) and Beclin 1.  Moreover, decorin induced autophagic flux 
(109), a widely known measurement of the cellular autophagic degradation 
activity (Fig. 8). As previously mentioned, Peg3 is a gene upregulated by decorin 
in the tumor stroma. Therefore, I sought to test its expression in ECs stimulated 
with decorin and found that it localized to the autophagosomes, and its 
expression pattern overlapped those of Beclin 1 and LC3.  
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This discovery described, for the first time, a function for a secreted 
proteoglycan, in the regulation of autophagy. Given the affinity of decorin for a 
wide range of RTKs, I wanted to investigate the mechanism that allowed decorin 
to induce autophagy in ECs. The most prominent receptor that stimulates EC 
proliferation, migration, and survival is VEGFR2. Previous studies have shown 
that decorin is a VEGFR2 binding antagonist in human extravillous trophoblasts 
(48).  I, therefore sought to determine the binding affinity of decorin to VEGFR2 
with solid-phase binding assays and found an interaction of the two molecules, 
which I then confirmed in pulldown experiments (35). Moreover, my study 
showed that VEGFR2 was required for decorin-evoked Beclin 1 and LC3 
expression as well as for Peg3 induction in ECs. Hence, the signaling cascade 
emanating from the decorin/VEGFR2 interaction leads to excessive autophagy 
in ECs with consequent inhibition of angiogenesis. These studies provided 
evidence that a soluble matrix molecule can regulate an intracellular catabolic 
program and described a novel role for PEG3 in this fundamental cell process. 
PEG3 is, indeed, required for decorin-evoked BECN1 and LC3 induction and is 
moreover responsible for maintaining Beclin 1 under basal conditions (35;110). 
Furthermore, de novo expression of Peg3 is sufficient to drive BECN1 
expression, confirming Beclin 1 as a direct target of Peg3 (111). The pro-
autophagic program evoked by decorin under the control of Peg3, Beclin 1, and 
LC3, precludes BCl-2 from this complex, a known autophagic inhibitor (112). Of 
Figure 7. Representative DIC/fluorescence images of MDEC treated with 200 nM decorin for 4 and 
6 h. White arrows indicate autophagosomes fully formed in the cytoplasm of the cells upon exposure 
to decorin. Nuclei were stained with DAPI. (Scale bar: ∼10 μm). Modified from Buraschi et al. (17) 
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note is that the initiation of this newly described autophagic signaling cascade 
by decorin is exclusively dependent on VEGFR2, the cardinal RTK for ECs, as 
it happens in full-serum conditions, unlike other autophagic stimuli such as 
nutrient deprivation or mTOR inhibition by rapamycin or Torin-1 (Fig. 9). Indeed, 
I showed that pharmacological inhibition of VEGFR2 via SU5416 abrogates 
decorin-induced EC autophagy. The binding of decorin to VEGFR2 differs from 
the previously discovered decorin/RTKs interactions insofar decorin does not 
induce internalization of VEGFR2. Decorin functions as a partial agonist of 
VEGFR2 by evoking non-canonical signaling cascades which are essential for 
autophagic activation. Two main pathways regulate autophagy: the pro-
autophagic AMPK/Vps34/ULK1/2/Beclin 1 cascade and the anti-autophagic 
Figure 8. Representative images of HUVEC cells treated with either decorin (200 nM) or bafilomycin 
(500 nM) alone or in combination and stained for LC3 (red) and Beclin 1 (green). Nuclei, blue. (Scale 
bar: ∼10 μm). 
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PI3K/Akt/mTOR/p70S6K pathway (113;114). Goyal et al., 2014 showed that the 
binding of decorin to VEGFR2 induces adenosine monophosphate kinase 
AMPK phosphorylation, thereby activating autophagy in an RTK-dependent 
manner. Mechanistically, depletion of VEGFR2 abolishes decorin-induced 
AMPK phosphorylation (115). This was the first study that linked VEGFR2 to 
the regulation of AMPK and autophagy as a whole. At the same time, decorin 
protractedly attenuates the PI3K/Akt/mTOR/p70S6K pathway, although it 
remains to be elucidated if this latter signaling cascade also depends on decorin 
binding to VEGFR2. Moreover, decorin promotes formation of pro-autophagic 
Vps34/Beclin 1 complexes, which in turn increase the levels of Peg3. The 
depletion of Vps34 prevents decorin-induced upregulation of Peg3 and 
induction of autophagy in ECs (115). Although the importance of the 
decorin/VEGFR2 interaction for sustained AMPK activation has been 
documented, no direct association between VEGFR2 and Vps34 or VEGFR2 
and AMPK has thus far been found. It is possible that the recruitment and /or 
activation of both AMPK and Vps34 is mediated by an intermediate kinase under 
the direct control of VEGFR2. Another possibility lies in the crosstalk among 
different RTKs, although these studies were performed exclusively in ECs, 
where RNAi-mediated depletion of VEGFR2 was functionally (and statistically) 
sufficient to abolish the effect of decorin. Together, these studies underscore 
the complexity of decorin signaling. Importantly, the requirement of VEGFR2 for 
AMPK-mediated activation of autophagy reveals a new potential target for the 
control of catabolism to suppress tumorigenesis. Following this study, Neill et 
al., 2017 identified the transcription factor EB TFEB, a master transcription 
factor for lysosomal biogenesis, as a key downstream molecule within the novel 
decorin/VEGFR2/AMPK/Peg3 cascade (116). In ECs, TFEB expression is 
induced by decorin, and Peg3 is necessary and sufficient for driving TFEB 
induction. Increasing concentration of Peg3, or decorin, drive TFEB expression, 
and depletion of Peg3 is sufficient to inhibit decorin-mediated TFEB expression 
(116). Taken together, these studies have described a function for decorin in 
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reprogramming the tumor stroma via direct induction of autophagy with 
consequent inhibition of EC migration and capillary morphogenesis, overall 
acting to combat tumor angiogenesis. Moreover, I have assigned a novel role 
to Peg3 in controlling this process downstream of VEGFR2 engagement.  The 
induction of Peg3 expression by decorin is critical for the activation of the 
autophagic program. This represents a significant improvement in the study of 
the biology of decorin as the previously described decorin-induced 
downregulation of β-catenin could also be explained by induced expression of 
Peg3. In a previous study, zebrafish embryos injected with Peg3 mRNA showed 
noticeable defects in tail development (106) which are strikingly similar to those 
of embryos injected with decorin (117). The noncanonical wingless-type MMTV 
integration site family (Wnt) pathway is known to regulate convergent extension 
(117). Thus, Peg3 and decorin could actively modulate the Wnt pathway during 
development and, in the same fashion, during tumor progression, causing 
suppression of β-catenin in cancer cells and enhanced autophagy in the 
endothelial compartment. Although autophagy is essential for normal 
development (118) and has been linked to cancer cell survival (119-121), 
induction of excessive autophagy can have profound deleterious effects on 
cancer growth and progression (122-126), leading to self-eating and self-killing 
(127;128). These studies undoubtedly influenced the field of Matrix Biology as 
they expanded understanding at the molecular level of how decorin functions 
as a tumor suppressor/anti-angiogenic factor, and stress the possibility that this 
multifaceted matrix constituent might be of therapeutic benefit in hindering the 
growth of the capillaries that are needed to bring nutrients to solid tumors.   
Following the publication of my studies in the Journal of the Proceedings of the 
National Academy of Science (PNAS) (35) (https://f1000.com/prime/718025940), 
other proteoglycans have been studied in the context of autophagy, and 
different signaling pathways have been elucidated. Biglycan is, like decorin, a 
member of the family of small leucine-rich proteoglycans and plays roles in 
angiogenesis (129) and inflammation (130). Emerging data suggest now that 
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biglycan can act in a pro-autophagic manner in cardiomyocytes subjected to 
reperfusion after ischemia (131), and in M1-type macrophages (132). On the 
contrary, perlecan, a basement membrane heparan sulfate proteoglycan, acts 
in an anti-autophagic manner (133). Studies involving conditional Hspg-/- mice 
revealed increased numbers of autophagosomes in muscle lacking perlecan 
and exhibits inhibition of the mTOR pathway when compared with their wild-
type counterparts (133). However, endorepellin, the domain V of perlecan, 
undertakes a wholly different function in autophagy. Following my study on the 
role of decorin in autophagy, endorepellin was found to bind similarly and signal 
through VEGFR2 to induce the pro-autophagic intermediaries AMPK, Beclin 1, 
Figure 9. Schematic representation of the signaling events evoked by decorin and endorepellin in 
endothelial cells upon high-affinity binding to VEGFR2. Decorin causes autophagy through induction 
of Peg3 and transcription of the autophagic genes Beclin 1 and LC3. Endorepellin activity, instead, 
requires both the α2β1 integrin and VEGFR2. Endorepellin evokes a physical down-regulation of 
both the α2β1 integrin and VEGFR2, with concurrent activation of the tyrosine phosphatase SHP-1, 
downstream attenuation of VEGFA transcription, and induces autophagy by inhibiting mTOR.  
41 
 
LC3, and p62 (134) while contemporaneously inhibiting mTOR. However, unlike 
decorin, endorepellin is unique in that it engages in dual receptor antagonism 
by binding simultaneously to VEGFR2 and 21 integrin (135) (Fig. 9). Thus, a 
single heparan sulfate proteoglycan shows opposing roles in finely regulating 
autophagy to prevent excessive or insufficient catabolism necessary for normal 
cellular homeostasis. These novel findings open new possibilities for future 
studies on the role of other matrix-associated molecules in the context of 
autophagy and angiogenesis. Notably, this work was cited by Klionsky et al., in 
the “Guidelines for the use and interpretation of assays for monitoring 
autophagy (3rd edition)”, Autophagy, 2016 (109). Dr. Klyonsky, with this 
periodical review, defines the acceptable standard criteria and assays for the 
study and understanding of autophagy among the international scientific 
community. Citing my work, the author recognizes decorin as an autophagic 
inducer, the first proteoglycan shown to be involved in this catabolic process, 
and PEG3 as a decorin-induced genomically imprinted tumor suppressor gene 













Decorin evokes mitophagy in breast carcinoma cells via Met 
The functional consequences of induction of autophagy via VEGFR2 and Peg3 
are of substantial interest as they could modulate vital cellular functions such as 
cell migration and mitochondrial membrane integrity through the loss of 
mitochondrial membrane potential (Δψm). Together with autophagy, mitophagy, 
the catabolic process that disrupts damaged mitochondria plays a crucial role 
in cell homeostasis. Although mitophagy can indicate initiation of apoptosis 
(136), it can also serve, in conjunction with autophagy, as a physiological 
survival mechanism that the cell adapts to avoid mutagenic events caused by 
reactive oxygen species that could trigger tumorigenesis. Dr. Neill, based on my 
studies on the role of decorin in autophagy, decided to investigate how decorin 
could affect cancer cell metabolism, a process strictly dependent on 
mitochondria. Supporting this line of research, and consistent with the activity 
of decorin to induce the tumor suppressor gene PEG3 is the previously 
described ability of decorin to induce mitostatin, an oncostatic mitochondrial 
protein (137). Mitochondria are vital biosynthetic hubs that provide 
macromolecules for cancer progression and angiogenesis (138). Moreover, 
mitochondrial biogenesis is known to be controlled by nuclear mitochondrial 
genes, which are also regulated by the proto-oncogene Myc (139), a target of 
decorin bioactivity. With these premises, a detailed study of the role of decorin 
on mitochondrial turnover in cancer cells was needed to elucidate decorin ability 
to suppress tumorigenesis under normoxia and to induce autophagy in the 
tumor stroma. Dr. Neill and I decided to utilize the triple-negative breast cancer 
cells, MDA-MB-231, that are highly responsive to decorin treatment through Met 
receptor, and interrogate their mitochondria activity. We found that decorin 
treatment of these cells resulted in mitochondrial DNA (mtDNA) depletion and 
prolonged complex respiratory turnover, two interpretive signs of mitochondrial 
autophagy (mitophagy) (140). We discover that in a mechanism similar to 
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VEGFR2 on ECs, decorin engages Met and induces mitophagy in triple-
negative and luminal breast carcinoma cells (140) (Fig.10). As for EC 
autophagy, tumor cell mitophagy depends on a decorin-inducible tumor 
suppressor gene. This essential decorin-induced gene is TCHP renamed 
mitostatin, a mitochondrial protein that shows numerous hallmarks of a 
traditional tumor suppressor gene such as inhibiting tumor cell migration, growth 
and proliferation, and simultaneous triggering of pro-apoptotic pathways 
(137;141). Mitostatin lacks in ~35% of human prostate cancers (141), and its 
decreased expression is associated with advanced cancer stages. Similarly to 
Peg3, mitostatin is indeed often lost or mutated in bladder and breast 
carcinomas (137), preventing its ability to induce mitophagy through 
Figure 10. Gallery of fluorescence images of MDA-MB-231 cells stably expressing the Su9-GFP 
transgene for mitochondrial network visualization. Cells were super-transfected with RNAi against 
mitostatin to determine the effect on the mitochondrial network as shown for the siScramble 
transfectants, treatment with decorin (200 nM), or decorin following mitostatin depletion. Arrows point 
at the healthy tubular mitochondrial network (siScramble), which aggregates and collapses upon 
decorin-treatment (middle panel). Depletion of mitostatin prevents decorin-induced mitochondrial 
fragmentation (right panel). All images were taken with the same exposure, gain, and intensity.  
(Scale bar ~ 10 μm). Modified from Buraschi et al. (40) 
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mitochondrial fragmentation of the cancer cells and highlighting its role as a 
powerful oncostatic protein. Upon decorin binding to Met on the cell surface of 
MDA-MB-231 breast carcinoma cells, PGC1, a critical mitochondrial 
biogenesis factor (142;143) is mobilized and stabilizes TCHP mRNA for 
mitostatin accumulation. This process can be blocked by siRNA-mediated 
abrogation of either PGC-1 or Met (140). Furthermore, depletion of mitostatin 
prevented decorin- or rapamycin-evoked mitophagy increased VEGFA 
expression, and inhibited decorin-evoked VEGFA suppression (140). These 
novel findings are highly significant because they establish mitostatin as a key 
regulator of tumor cell mitophagy and angiostasis. Elucidating this pathway, we 
described unique molecular cooperation between a mitophagic effector and a 
proto-oncogene orchestrated by the specific direct binding of decorin to RTKs 
on the surface of cancer cells. Decorin induces fragmentation of the 
mitochondrial network via induction of mitostatin and loss of the mitochondrial 
membrane potential (m), an early sign of mitochondrial dysfunction, and 
parkin recruitment (140). Altogether, this might cause an efflux of Ca2+ from the 
endoplasmic reticulum to the mitochondrial matrix, evoking mitophagy. 
Mitostatin may indirectly stimulate Parkin expression, and the PTEN induced 
kinase 1 (PINK1) activity for targeting and ubiquitination of mitochondrial 
proteins (144).  Collectively, we demonstrated that decorin-evoked Met 
signaling in breast cancer cells is essential for the induction of mitophagy and 
consequent cell growth arrest. Mitophagy of the tumor parenchyma, in 
conjunction with stromal autophagy, depicts a double mechanism of action for 
decorin that directly suppresses cancer growth and tumor neovascularization. 
Nanomolar concentrations of soluble decorin are sufficient to reprogram the 
signaling signature of the tumor stroma towards a protracted oncosuppressive 
microenvironment. The mitochondrial oxidative phosphorylation system, 
OXPHOS, is crucial for cancer cell proliferation, survival, migration, 
angiogenesis, and metastasis (145). Based on our novel observation that 
decorin compromises the OXPHOS system via a signaling pathway that 
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requires mitostatin (140), we hypothesize that decorin-evoked tumor cell 
mitophagy could contribute to its oncosuppressive and anti-metastatic 
properties. Further, the PINK1/Parkin pathway is directly involved in respiratory 
chain turnover (146), a central signaling pathway regulated by decorin and 
mitostatin. Our results provide the first evidence that a soluble constituent of the 
extracellular matrix can affect the intracellular digestive machinery, and could 
lead to the development of new therapeutics concurrently targeting the tumor 
stroma and cancer cells. We have unveiled for the first time a dual mechanism 
for a secreted proteoglycan in inducing autophagy in ECs and mitophagy in 

















Significance and conclusions 
Breast cancer remains the most common malignancy in women in the UK and 
the world, with a steadily increasing incidence (147;148). Further delineation of 
the molecular underpinnings linking tumor initiation, progression, and 
metastases could lead to improved treatment modalities for breast cancer. 
Since angiogenesis and autophagy are both hallmarks of tumor initiation and 
progression from signals originating in the matrix, we sought to understand the 
role of a significant player of the extracellular matrix, decorin in shaping these 
events.  My studies provide a novel concept whereby decorin, a soluble 
extracellular and circulating proteoglycan, regulates tumor initiation by 
modulating the tumor microenvironment. Because of its highly diverse and 
broad binding repertoire, decorin could be considered a “guardian from the 
matrix.” Decorin functions as a ‘guardian’ in the context of constraining the 
activity of multiple RTKs, thereby acting on both the cancer proper (via EGFR 
and Met) and the tumor stroma (via VEGFR2 in ECs). The concept of a master 
regulator of gene expression, such as p53, a guardian of the genome, and Myc, 
a gene that affects ~1,500 genes in cancer progression, is widely accepted. The 
described studies challenge current paradigms and provide a new concept 
whereby decorin affects autophagy,  independently of nutrient deprivation. 
Three areas make these research studies highly innovative and 
groundbreaking:  [1] The finding that soluble decorin antagonizes Met receptor 
activity and downregulates -catenin and Myc levels counteracting tumor 
growth. Besides, decorin prevents migration of bladder cancer cells by binding 
with high affinity to IGF-I and IGF-IR. [2] The discovery that stromal-derived 
decorin evokes an excessive pro-autophagic program in ECs by activating 
AMPK, an energy sensor kinases, downstream of VEGFR2   and concurrently 
inducing TFEB and Peg3, a novel master regulator of autophagy.  This is the 
first description that a secreted proteoglycan affects AMPK independently of 
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nutrient deprivation. Inducing the autophagic response could potentiate the anti-
angiogenic effects of decorin on ECs, even in the absence of nutritional stress. 
[3] The discovery that decorin induces mitophagy in breast carcinoma cells via 
a partial agonistic activity on Met, unraveling a novel mechanism of action that 
involves a direct interaction between the decorin-inducible gene mitostatin and 
PGC-1. Metabolic reprogramming is one of the hallmarks of cancer, as it 
provides survival opportunities for cancer cells undergoing stress. Decorin 
stabilizes the expression of mitostatin through PGC-1. This is significant as it 
is the first-ever described link between metabolic reprogramming and decorin.  
Thus, decorin employs both the stroma (vascular endothelium) and the tumor 
proper via VEGFR2 and Met to exert profound signaling activities (Fig. 11). 
Decorin reprograms the tumor microenvironment and tumor parenchyma 
toward a pro-catabolic state by evoking EC autophagy and tumor cell 
mitophagy. This discovery came full circle as autophagic stimuli regulate 
decorin itself (149;150). These concerted research lines should firmly establish 
the functional roles of decorin in tumor angiogenesis and oncosuppression. The 
Figure 11. Schematic representations delineating (A) the autophagic pathway evoked by decorin in 
endothelial cells via binding to VEGFR2 and (B) the classic growth inhibitory functions and (C) novel 
promitophagic activities of decorin in tumor cells. Modified from Neill et al.(33) 
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discovery of dual decorin activity opens new possibilities for anti-angiogenic and 
anti-oncogenic therapies. Moreover, the mounting evidence that decorin targets 
the tumor vasculature suggests that decorin might be an ideal adjuvant 
candidate in the treatment of solid malignancies. There are several advantages 
of using decorin as primary or adjuvant therapy.  Being a soluble protein, decorin 
could concurrently interact with many tumor cells at distant sites and should not 
trigger an immune response. Long term goals could focus on understanding the 
mode of action of decorin at the molecular level, decipher the decorin-induced 
signaling network operating during oncogenesis and tumor angiogenesis, and 
investigate its novel function as a soluble pro-autophagic molecule.  These 
newly established concepts of the molecular mechanisms of action of decorin 
have significantly advanced the matrix and cancer biology fields, especially as 
they relate to understanding growth regulation, cross-talk between cancer and 
stroma, and tumor angiogenesis, all central issues in tumor progression and 
metastasis (18;90). Decorin’s bioactivity would aid in signal integration, as 
circulating decorin (61;151-153) would modulate multiple RTKs with varying 
kinetics as a mechanism to subdue cancer growth. In conclusion, the 
extracellular matrix is becoming a key hotspot of potential diagnostic indicators, 
prognostic markers, and therapeutic targets, particularly when it comes to 
proteoglycans. Decorin is extremely attractive as an innovative therapeutic 
agent given its crucial active roles in both angiogenesis and autophagy, two 
biological processes highly linked to tumorigenesis, metastasis, and 
chemoresistance (154). The behavioral pattern of decorin, in the extracellular 
matrix, is directly related to the etiology and pathobiology of tumor progression 
and metastasis, and could potentially lead to novel avenues of cancer treatment 
by employing an anti-oncogenic protein capable of targeting various solid 
tumors and their metastases, particularly those enriched in RTKs. In conclusion, 
a deeper understanding of the molecular mechanisms of action of decorin and, 
perhaps, other matrix components could help us design novel strategic adjuvant 
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